Ss 31: Mechanism of Action
17 PubMed CitationsExpert ReviewedGMP CertifiedLast Reviewed: April 2026
Mechanism of Action
Primary Target: Cardiolipin (CL) on the Inner Mitochondrial Membrane
SS-31 does NOT bind to a protein receptor. Instead, it binds directly to cardiolipin (CL) — an anionic phospholipid unique to the IMM that is critical for organizing the electron transport chain (ETC) into functional supercomplexes (respirasomes). The binding is driven by two forces:[1][2]
- Electrostatic: D-Arg and Lys (cationic residues) bind the anionic phosphate head groups of CL
- Hydrophobic: Dmt and Phe (aromatic residues) intercalate into the hydrophobic acyl chain region of CL
- Selectivity: SS-31 does NOT bind zwitterionic phospholipids (e.g., phosphatidylcholine, phosphatidylethanolamine) — purely selective for anionic CL
Downstream Cascade
| Step | Mechanism | Functional Outcome |
|---|---|---|
| 1. CL binding | High-affinity IMM localization (5,000×) | Prevents pathological CL/cytochrome c peroxidase activity[2] |
| 2. Cyt c preservation | Stabilizes CL → preserves cyt c electron carrier function | Facilitates Complex III→IV electron transfer → ↑ATP synthesis[1] |
| 3. Supercomplex assembly | Stabilizes ETC respirasomes | Optimizes oxidative phosphorylation coupling efficiency[5] |
| 4. Cristae preservation | Optimizes IMM curvature | Prevents mitochondrial swelling and fragmentation[4] |
| 5. mPTP inhibition | Prevents mitochondrial permeability transition pore opening | Reduces ischemia-reperfusion injury, apoptosis[6] |
| 6. NF-κB inhibition | Prevents p65 nuclear translocation | Reduced pro-inflammatory cytokine production[7] |
| 7. NLRP3 inhibition | Reduces inflammasome activation | ↓ IL-1β, IL-18 production[7] |
| 8. Nrf2/SIRT1/PGC-1α | HO-1 upregulation; mitochondrial biogenesis | Antioxidant gene expression; restored mitochondrial mass[5] |
| 9. BDNF signaling | Enhances synapsin-1, PSD-95, p-CREB | Neuroprotection, cognitive function[8] |
vs. Related Mitochondrial Compounds
| Compound | Primary Target | Membrane Potential Dep. | Key Difference |
|---|---|---|---|
| SS-31 (elamipretide) | Cardiolipin (IMM) | No | Reaches severely dysfunctional mitochondria; no depolarization at high concentrations |
| MitoQ | Mitochondrial matrix | Yes (requires ΔΨm) | Depolarizes at high doses; cannot reach severely damaged mito |
| NAC (N-acetylcysteine) | Cytosolic GSH replenishment | No | Stoichiometric scavenging; not concentrated at ROS source |
| MOTS-c | Folate cycle / Nuclear ARE | No | Mitokine; targets nuclear gene regulation via AMPK/Nrf2 rather than direct ETC |
References
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology. 2014;171(8):2029-2050.
- Birk AV, Liu S, Soong Y, et al. The Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting with Cardiolipin. Journal of the American Society of Nephrology. 2013;24(8):1250-1261.
- FDA Press Announcement. FDA approves first treatment for rare genetic heart muscle disease. September 19, 2025.
- Campbell MD, Duan J, Bhatt SK, et al. Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Free Radical Biology and Medicine. 2019;134:268-281.
- Sabbah HN. Elamipretide (SS-31) improves mitochondrial function and prevents cellular apoptosis in heart failure and its comorbidities. Expert Opinion on Investigational Drugs. 2021;30(12):1227-1244.
- Sabbah HN, Gupta RC, Kohli S, et al. Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure. Circulation: Heart Failure. 2016;9(2):e002206.
- Sabbah HN, Klewer SE, O'Brien T, et al. Elamipretide and NF-κB/NLRP3 inflammasome inhibition. Biomedicine & Pharmacotherapy. 2025;183:118056.
- Zhao W, Xu Z, Cao J, et al. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic integrity, and cognition in an Alzheimer's disease model. Scientific Reports. 2019;9(1):13137.
- Thompson WR, Hornby B, Manuel R, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genetics in Medicine. 2024;101138.
- Karaa A, Haas R, Goldstein A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90(14):e1212-e1221.
- Birk AV, Chao WM, Bracken C, et al. Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. British Journal of Pharmacology. 2014;171(8):2017-2028.
- Cousins D, Brar P, McFarlane T, et al. Phase 2 study of elamipretide (SS-31) in age-related macular degeneration (ReCLAIM-2). Ophthalmology Retina. 2023.
- Saad A, Herrmann SMS, Eirin A, et al. Phase 2a clinical trial of mitochondrial protection (elamipretide) during stent revascularization in patients with atherosclerotic renal artery stenosis. Circulation: Cardiovascular Interventions. 2017;10(9):e005130.
- Dai DF, Hsieh EJ, Chen T, et al. Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides. Circulation: Heart Failure. 2013;6(5):1067-1076.
- Chiao YA, Rabinovitch PS, Bhatt SK, et al. Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice. eLife. 2020;9:e55513.
- Lincoff AM, Bhatt DL, Fischell T, et al. Elamipretide and post–cardiac arrest outcomes (EMBRACE STEMI). American Heart Journal. 2014;168(2):222-228.
- FDA Integrated Review NDA 215244 — Forzinity (elamipretide) Approval Package. 2025.
Related Research Questions
Want the complete research review?
View Full Ss 31 Research Page→FOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.
